News and Trends 18 Jul 2017
Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche
Shire has bought exclusive worldwide rights to develop and commercialize a bispecific antibody from Novimmune that could improve the treatment of hemophilia A. Novimmune is a biotech from Geneva that specializes in developing antibodies. Back in 2015, it struck a research collaboration with Baxalta, which has since been acquired Shire. The Irish pharma has now decided to […]